The aim was to compare the 5 yr survival in patients with rheumatoid arthritis (RA) alone, bronchiectasis (Br) alone and RA plus Br (RA-Br). A case-control study was carried out in which 32 patients with RA-Br were matched for age (within 5 yr), sex and (where possible) disease duration with 32 patients with RA alone. An additional comparison group of 31 unselected patients with Br was chosen. All patients were followed for 5 yr. Patients with RA-Br were 7.3 times more likely to die than the general population, 5.0 times more likely than the RA group and 2.4 times more likely than the Br group. An increased risk of death within the RA-Br group was associated with a history of smoking, more severe RA and steroid usage. The co-existence of RA and Br is associated with a poor 5 yr survival.
R arthritis (RA) and bronchiectasis (Br) occur together more frequently than would be expected by chance [1] [2] [3] . Walker and Wright [1] found Br in 3.1% of 516 patients with definite or classical RA, and 0.3% of 301 patients with osteoarthritis. In all cases where the temporal sequence could be assessed, the Br preceded the development of RA. Solanki and Neville [2] found definite RA in four (5.2%) of 77 patients with Br. Again the Br preceded the RA in all four cases. On the other hand, a group from Boston [3] reported that Br occurred after the onset of RA in 18 out of 23 patients with both conditions. The exact mechanism of the association is unknown. It has been suggested that the presence of chronic suppurative infection in the lung may act as a trigger for the development of RA. However, this would not explain those cases where the RA comes first. Alternatively, patients who have, or are going to develop, RA may have a deficit in handling bacterial infections.
There is no evidence that patients with pre-existing Br have more severe RA than those without Br [1, 4] . It is not clear, however, whether the co-existence of the two conditions influences survival. Patients with RA have a reduced life expectancy [5] . Deaths from all causes are increased and, in particular, deaths from infection, respiratory disease, renal and gastrointestinal disease [6] . Since patients with Br have recurrent lung infections, it might be anticipated that the co-existence of Br and RA would further reduce survival. In order to explore this issue, we have examined the 5 yr survival of a group of patients with RA-Br and compared it with the survival of a control group of RA patients matched for age, sex and disease duration, and a group of patients with Br alone.
METHODS
In 1987, we identified 32 patients with RA-Br from our diagnostic index of over 3000 patients [4] . In 30 of the patients, the Br preceded the RA. They were matched for sex and age (within 5 yr) with 32 patients who had RA alone. Where more than one possible match was identified, the RA control with the disease duration closest to that of the case was selected: thus, 25 pairs had E5 yr difference in disease duration, three had 6-10 yr difference in disease duration and four had e11 yr difference in disease duration (maximum 23 yr). A further 31 patients with Br alone were identified from the local chest clinic. Because of the small numbers of patients available, they could not be matched to either of the other groups, but the sex ratio, the age of onset and the duration of Br were very similar to the RA-Br group [4] . All 95 patients were followed for 5 yr; 13 died in hospital and three at home. It was possible to examine the records of the terminal illness in 10 of the hospital deaths.There were two post-mortem examinations. Death certificates were obtained for all who died. The cause of death was taken as the underlying cause on the death certificate and coded using the 9th Revision of the International Classification of Diseases (ICDR9) [7] .
Person years at risk (pyr) were calculated for each individual from enrolment into the study until the fifth anniversary or death. The expected number of deaths for each group was estimated by applying the age-and sex-adjusted death rates for the population of England and Wales to the pyr for that group. Standardized mortality ratios (SMRs) were calculated by dividing the observed by the expected number of deaths.
Clinical and laboratory variables measured at the beginning of the study were examined for their ability to predict mortality over the next 5 yr in the RA-Br group.
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Correspondence to: D. R. Swinson. RESULTS The demographic details of the three groups are shown in Table I . Although the Br alone group were not matched to the other groups, they had a similar mean age and disease duration. At baseline, the RA-Br group had a lower FEV 1 than either of the other two groups (see Table II ). The RA and RA-Br groups had similar RA disease severity, as judged by a baseline measure of physical function [the Health Assessment Questionnaire (HAQ)] [4] and of radiological damage (the Larsen score) [4] .
During the 5 yr follow-up period, there were 10 deaths in the RA-Br group, two in the RA group and four in the Br group (Table III) .
The SMR for the RA-Br group was 7.3 times higher than expected, whereas that in the RA group was no different from that expected in a group with this age and sex distribution. The Br group had a mortality rate which was twice the expected rate, but the 95% confidence limits include unity.
In the group with RA alone, there was one death from ischaemic heart disease and one from bronchial carcinoma. All four deaths in the Br group were due to respiratory infection and/or respiratory failure. One patient with Br who died also had chronic lymphatic leukaemia. In the RA-Br group, six deaths were attributed to bronchopneumonia, two to cor pulmonale, one to cardiac failure and one to malignancy.
We looked within the RA-Br group for predictors of mortality (Table IV) . Patients with severe RA (nodules, poor grip strength), worse lung disease (FEV 1 Q 30% of predicted), a history of smoking or on steroid therapy had an increased risk of death in the next 5 yr. In laboratory terms, a raised white cell count and circulating immune complexes carried a high risk of mortality. Many of the confidence intervals include unity, reflecting the small size of the study.
DISCUSSION
The study demonstrates that patients with RA-Br are 7.3 times more likely to die during a 5 yr follow-up period than the general population, 5.0 times more likely to die than those with RA alone and 2.4 times more likely to die than those with Br alone. These differences cannot be attributed to age, sex or RA disease duration or severity. These results emphasize very starkly the importance of co-morbidity in the prognosis of RA patients.
Previous studies have shown that poor functional class is an important predictor of mortality [8] [9] [10] [11] . A significant association between mortality and a number of extra-articular features [12] , including the presence of circulating immune complexes [13] , has also been reported. However, few studies have examined the effect of co-morbidity.
A number of studies have shown an increased risk of death from infection and respiratory disease (reviewed by Pincus [5] ). In ICD9, pneumonia is grouped with respiratory deaths. In a recent post-mortem series, Suzuki et al. [14] reported that 14 out of 81 (17%) deaths in RA patients were due to pneumonia. With these findings in patients with uncomplicated RA, it is perhaps not surprising that those with co-existent chronic suppurative lung disease should fare even worse. The majority of deaths in the RA-Br patients in this study (60%) were attributed to pulmonary infection.
The RA-Br patients also fared worse than the Br group; as the cause of death in each group was predominantly pulmonary, it is possible that differences in the lung pathology might account for the worse prognosis in the RA-Br group. Paradoxically, a simple clinical grading system showed that at the outset [4] the Br patients had more severe lung disease than the RA-Br patients, as might be expected of patients attending a chest clinic. In contrast, spirometry showed lower FEV 1 s and, in particular, a significant excess of fixed airways obstruction in the RA-Br patients. This provides one explanation for the difference in mortality between the two groups given the known influence of the FEV 1 in patients with airways obstruction [15] and the propensity of patients with RA to develop small airways obstruction [16] . These observations have implications for the clinical management of patients with co-existing RA and Br.
